R&D channel feed – Endpoints News

R&D channel feed

Make that 2 approved RNAi drugs at Alnylam after the FDA offers a speedy OK on ultra-rare disease drug

6 years ago

Opdivo/Yervoy combo for melanoma fails in key patient population

6 years ago

Vertex's stellar quarter carries on with French reimbursement deal

6 years ago

Kymera hands the helm to Novartis vet — and founding CSO — Nello Mainolfi

6 years ago

AbbVie lines up a new preclinical R&D alliance with the dealmakers at natural killer player Dragonfly

6 years ago

Novartis is eyeing a multibillion-dollar MedCo buyout as Jersey biotech nears NDA — reports

6 years ago

London AI upstart, which counts Novartis as a customer, can teach your computer to read

6 years ago

Wellington lines up a $393M bankroll for its next round of private biotech bets — and they’re likely thinking big

6 years ago

As uterine race with AbbVie heats up, Myovant eyes FDA approval with trial results from prostate cancer

6 years ago

In a landmark first glimpse of human data from Vertex, CRISPR/Cas9 gene therapy signals early benefit

6 years ago

In rare political foray, top biotech investors urge Congress to reject drug pricing bill

6 years ago

Pfizer gets biosimilar approved for Humira, setting up competition — in 2023

6 years ago

Merck’s $1B cash gamble pays off with a surprising PhIII cardio success for Bayer’s heart drug vericiguat

6 years ago

Eyeing one of the first RNAi therapies and cholesterol blockbuster, MedCo shows detailed inclisiran data

6 years ago

Alkermes forges $950M biotech buyout deal in a bold bet on an early-stage CNS drug platform

6 years ago

After a late-stage miss, Novartis touts another Entresto analysis to convince the FDA to expand the blockbuster's label

6 years ago

Novartis is axing 150 early discovery jobs as CNIBR shifts focus to the development side of R&D

6 years ago

Karuna clears PhII hurdle in schizophrenia, takes aim at a pivotal in blockbuster hunt — shares soar

6 years ago

Novartis scores its latest FDA OK — this time for a new sickle cell disease drug picked up in a $665M deal

6 years ago

Five drugs, including two Novartis therapies, win EMA endorsement

6 years ago

Atomwise's X-37 spinout gets $14.5 million to launch AI discovery efforts

6 years ago

UCB adds on more positive PhIII data for IL-17A/17F inhibitor bimekizumab, clearing a path to the FDA

6 years ago

Roche bags 'breakthrough' anti-fibrosis drug in $1.4B biotech buyout deal

6 years ago

Novartis spinout’s first anti-aging PhIII is a flop, so now they’ll turn to Parkinson’s challenge as shares wilt

6 years ago

First page Previous page 222 223 224225226 227 228 Next page Last page